MedTrace Logo

A Study of APL-10456-Vaccine

NCT07399132 · Status: ACTIVE_NOT_RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 144

Last updated 2026-05-27

No results posted yet for this study

Summary

AP09CP01 is a Phase 1, Randomized, Double-Blind, Placebo-Controlled, Two-Part Study which is conducted in Australia. The main purpose of this research study is to evaluate the safety, side effects, and immune response of APL-10456-Vaccine, a Rhinovirus (RV) Vaccine, when compared with a placebo in Younger and Older Healthy Volunteers

Conditions

  • Rhinovirus

Interventions

DRUG

APL-10456-Vaccine

3 cohorts are planned for Part A and Part B

OTHER

Placebo

Placebo (a saline) is comparator to study vaccine

Sponsors & Collaborators

  • Apollo Therapeutics Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-02-16
Primary Completion
2027-05-18
Completion
2027-05-18

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07399132 on ClinicalTrials.gov